Developer docs
API playgroundTry for free, no card

Search company profiles

Medsol

Full company profile

uuid000tut1

Namestring
Medsol
Legal namestring
Medsol India Overseas Pvt. Ltd.
Websiteurl
medsolindia.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Medsol India Overseas Pvt. Ltd. is a privately held Indian pharmaceutical company founded in 2010 and headquartered in Noida, with 51–100 employees. The company focuses on the osteoporosis therapeutic segment, marketing a branded portfolio of generic bisphosphonate formulations including Alensol (Alendronate), Alensol-D (Alendronate + Vitamin D), Osteoplus (Risedronate), and Ibanplus (Ibandronic acid), with Zolendronic Acid (Vertesol) in development. Adjacent products include the pain reliever Tremsol (Tramadol/Acetaminophen), the GI therapy Paro-D (Pantoprazole/Domperidone), and dietary supplements Fresh-AD and Calcite.

Medsol operates a sales-led go-to-market through a direct field force of Medical Sales Representatives that engages doctors, hospitals, and pharmacies across India, with no disclosed international sales. The company complements its product business with three additional service lines: patient education and support (medication reminders, meal planning, lifestyle management delivered in hospital and home settings), pharmaceutical sales force capability training (product training, sales training, territory management), and prescription-channel distribution of branded products.

The company is founder-owned (established by three pharmaceutical industry professionals), with no disclosed external funding, acquisitions, partnerships, patents, or awards in the available data. Pricing is not publicly disclosed, and revenue figures have not been reported. The stated strategic vision is to rank among the top 50 pharmaceutical companies in India and pursue leadership in chosen global markets, though current operations remain concentrated in the domestic Indian market.

Short descriptiontext

Medsol India Overseas Pvt. Ltd. is a privately held Indian pharmaceutical company founded in 2010 that markets branded generic bisphosphonate formulations focused on osteoporosis, alongside pain, GI, and supplement products, selling to doctors, hospitals, and pharmacies through a direct field sales force in India.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNoida, India
HQ citystring
Noida
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, osteoporosis therapeutics, bisphosphonate medications, patient education services, pharmaceutical sales training
Industry1 code
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Products
TypeOne Time License
Description

Sale of branded pharmaceutical products including osteoporosis medications (Alendronate, Risedronate, Ibandronic acid), pain relievers (Tramadol/Acetaminophen), and supplements. Products are sold to healthcare providers and patients through prescription channel.

medsolindia.com
2Training Services
TypeProfessional Services
Description

Sales force capability building through product training, sales training, territory management, and pre-interview training seminars for pharmaceutical sales professionals.

medsolindia.com
3Patient Education Services
TypeProfessional Services
Description

Patient education and support services including medication reminders, meal planning, and lifestyle management programs delivered in hospital and home settings.

medsolindia.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Marketing or Sales, Personnel, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Medsol develops, manufactures, and markets branded pharmaceutical formulations with a primary focus on the osteoporosis therapeutic segment, including bisphosphonate products (Alensol/Alendronate, Osteoplus/Risedronate, Ibanplus/Ibandronic acid) and combination products such as Alensol-D (Alendronate + Vitamin D). Alongside prescription drugs, the company sells pain management (Tremsol), gastrointestinal (Paro-D), and dietary supplement products (Fresh-AD, Calcite). Medsol also delivers patient education and support services in hospital and home settings, and provides pharmaceutical sales force capability training (product training, sales training, territory management).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Medsol is a pharmaceutical company focused on the Osteoporosis therapeutic segment. The company offers a portfolio of bisphosphonate medications including Alensol™ (Alendronate), Osteoplus™ (Risedronate), Ibanplus™ (Ibandronic acid), and combination products like Alensol-D™ and Paro-D™. In addition to prescription medications, Medsol markets dietary supplements including Fresh-AD™ (vitamins, minerals & Ginseng) and Calcite™ (calcium & Vit D). The company also provides healthcare services including patient education programs, medication reminders, meal planning, lifestyle management, and comprehensive sales force training services for the pharmaceutical industry.

Product and service10 records
1Alensol
CategoryOsteoporosis prescription drug (bisphosphonate)
2Alensol-D
CategoryOsteoporosis prescription drug (bisphosphonate + Vitamin D)
3Osteoplus
CategoryOsteoporosis prescription drug (bisphosphonate)
4Ibanplus
CategoryOsteoporosis prescription drug (bisphosphonate)
5Tremsol
CategoryPain management prescription drug
6Paro-D
CategoryGastrointestinal prescription drug
7Fresh-AD
CategoryDietary supplement
8Calcite
CategoryDietary supplement
9Patient Education and Support Services
CategoryHealthcare support services
10Pharmaceutical Sales Force Capability Training
CategoryPharmaceutical sales training services
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian formulation-driven pharma with branded generics portfolio covering chronic and therapeutic areas; comparable in sales-led distribution model and India-domestic revenue mix.

TypeDirect peer
Description

India-based mid-sized pharma with branded formulations, women's health, and chronic-disease therapies; comparable scale and specialty-care orientation.

TypeDirect peer
Description

Mid-tier Indian listed pharma company specializing in branded generics across multiple therapeutic areas, with strong direct field-sales presence and a specialty-chronic-disease portfolio that overlaps with Medsol's osteoporosis franchise.

4USV Private Limited
TypeDirect peer
Description

India-based, founder-owned mid-size pharma company with branded formulations across specialty therapeutic areas including osteoporosis (Ibandronate). Closest comparable on size, ownership profile (private), branded-generic focus, and India-only footprint.

TypeRegional player
Description

Indian branded-generics pharma with specialty and chronic-care therapeutic areas; comparable in formulation focus and India field-sales distribution model.

TypeBroad incumbent
Description

One of India's largest pharmaceutical incumbents with broad branded-formulations portfolio covering respiratory, cardiology, and chronic-disease categories that include osteoporosis therapeutics.

TypeRegional player
Description

India-headquartered specialty pharma with branded oncology and chronic-disease formulations; relevant comparable for specialty branded strategy though larger and more diversified than Medsol.

TypeBroad incumbent
Description

One of India's largest domestic pharma companies with extensive branded generics portfolio across chronic and acute segments; broader scale and reach than Medsol but overlapping chronic-disease franchises.

TypeDirect peer
Description

Indian specialty pharma focused on chronic-disease branded formulations sold through specialist field force; highly comparable chronic-care specialty positioning and sales model to Medsol.

TypeDirect peer
Description

Private Indian pharma company with a broad branded-generics portfolio sold through field sales force to physicians and hospitals. Similar size bracket, founder-led, multi-therapeutic branded focus, and direct sales-led GTM.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medsol

Pharmaceuticalsmedsolindia.com

Medsol India Overseas Pvt. Ltd. is a privately held Indian pharmaceutical company founded in 2010 that markets branded generic bisphosphonate formulations focused on osteoporosis, alongside pain, GI, and supplement products, selling to doctors, hospitals, and pharmacies through a direct field sales force in India.

What Medsol does

Medsol India Overseas Pvt. Ltd. is a privately held Indian pharmaceutical company founded in 2010 and headquartered in Noida, with 51–100 employees. The company focuses on the osteoporosis therapeutic segment, marketing a branded portfolio of generic bisphosphonate formulations including Alensol (Alendronate), Alensol-D (Alendronate + Vitamin D), Osteoplus (Risedronate), and Ibanplus (Ibandronic acid), with Zolendronic Acid (Vertesol) in development. Adjacent products include the pain reliever Tremsol (Tramadol/Acetaminophen), the GI therapy Paro-D (Pantoprazole/Domperidone), and dietary supplements Fresh-AD and Calcite.

Medsol operates a sales-led go-to-market through a direct field force of Medical Sales Representatives that engages doctors, hospitals, and pharmacies across India, with no disclosed international sales. The company complements its product business with three additional service lines: patient education and support (medication reminders, meal planning, lifestyle management delivered in hospital and home settings), pharmaceutical sales force capability training (product training, sales training, territory management), and prescription-channel distribution of branded products.

The company is founder-owned (established by three pharmaceutical industry professionals), with no disclosed external funding, acquisitions, partnerships, patents, or awards in the available data. Pricing is not publicly disclosed, and revenue figures have not been reported. The stated strategic vision is to rank among the top 50 pharmaceutical companies in India and pursue leadership in chosen global markets, though current operations remain concentrated in the domestic Indian market.

Medsol firmographics

Firmographics
Name
Medsol
Legal name
Medsol India Overseas Pvt. Ltd.
Website
https://medsolindia.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
51–100 employees
Short description
Medsol India Overseas Pvt. Ltd. is a privately held Indian pharmaceutical company founded in 2010 that markets branded generic bisphosphonate formulations focused on osteoporosis, alongside pain, GI, and supplement products, selling to doctors, hospitals, and pharmacies through a direct field sales force in India.
Ownership category
akta.pro rank

Medsol industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pharmaceutical manufacturing
  • Osteoporosis therapeutics
  • Bisphosphonate medications
  • Patient education services
  • Pharmaceutical sales training

Where Medsol is headquartered

Location

Headquarters

HQ city
Noida
HQ country
India
HQ region
Asia

Offices1 record

Markets served

Medsol business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Marketing or Sales, Personnel, Operations, Technology or R&D

Revenue model

  1. Pharmaceutical Products: Sale of branded pharmaceutical products including osteoporosis medications (Alendronate, Risedronate, Ibandronic acid), pain relievers (Tramadol/Acetaminophen), and supplements. Products are sold to healthcare providers and patients through prescription channel.
  2. Training Services: Sales force capability building through product training, sales training, territory management, and pre-interview training seminars for pharmaceutical sales professionals.
  3. Patient Education Services: Patient education and support services including medication reminders, meal planning, and lifestyle management programs delivered in hospital and home settings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Medsol product offering

Product offering

Core offering

Medsol develops, manufactures, and markets branded pharmaceutical formulations with a primary focus on the osteoporosis therapeutic segment, including bisphosphonate products (Alensol/Alendronate, Osteoplus/Risedronate, Ibanplus/Ibandronic acid) and combination products such as Alensol-D (Alendronate + Vitamin D). Alongside prescription drugs, the company sells pain management (Tremsol), gastrointestinal (Paro-D), and dietary supplement products (Fresh-AD, Calcite). Medsol also delivers patient education and support services in hospital and home settings, and provides pharmaceutical sales force capability training (product training, sales training, territory management).

Product overview

Medsol is a pharmaceutical company focused on the Osteoporosis therapeutic segment. The company offers a portfolio of bisphosphonate medications including Alensol™ (Alendronate), Osteoplus™ (Risedronate), Ibanplus™ (Ibandronic acid), and combination products like Alensol-D™ and Paro-D™. In addition to prescription medications, Medsol markets dietary supplements including Fresh-AD™ (vitamins, minerals & Ginseng) and Calcite™ (calcium & Vit D). The company also provides healthcare services including patient education programs, medication reminders, meal planning, lifestyle management, and comprehensive sales force training services for the pharmaceutical industry.

Differentiator

Problem solved

Functional benefit

Products and services

  • Alensol
  • Alensol-D
  • Osteoplus
  • Ibanplus
  • Tremsol
  • Paro-D
  • Fresh-AD
  • Calcite
  • Patient Education and Support Services
  • Pharmaceutical Sales Force Capability Training

Companies that use Medsol

Customer profile

Segments2 records

Ideal customer profiles3 records

Medsol technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Medsol partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Medsol competitors and assessment

Company assessment

Direct peers

  • Ipca Laboratories: Indian formulation-driven pharma with branded generics portfolio covering chronic and therapeutic areas; comparable in sales-led distribution model and India-domestic revenue mix.
  • Emcure Pharmaceuticals: India-based mid-sized pharma with branded formulations, women's health, and chronic-disease therapies; comparable scale and specialty-care orientation.
  • Alkem Laboratories: Mid-tier Indian listed pharma company specializing in branded generics across multiple therapeutic areas, with strong direct field-sales presence and a specialty-chronic-disease portfolio that overlaps with Medsol's osteoporosis franchise.
  • USV Private Limited: India-based, founder-owned mid-size pharma company with branded formulations across specialty therapeutic areas including osteoporosis (Ibandronate). Closest comparable on size, ownership profile (private), branded-generic focus, and India-only footprint.
  • Eris Lifesciences: Indian specialty pharma focused on chronic-disease branded formulations sold through specialist field force; highly comparable chronic-care specialty positioning and sales model to Medsol.
  • Macleods Pharmaceuticals: Private Indian pharma company with a broad branded-generics portfolio sold through field sales force to physicians and hospitals. Similar size bracket, founder-led, multi-therapeutic branded focus, and direct sales-led GTM.

Regional players

  • Alembic Pharmaceuticals: Indian branded-generics pharma with specialty and chronic-care therapeutic areas; comparable in formulation focus and India field-sales distribution model.
  • Natco Pharma: India-headquartered specialty pharma with branded oncology and chronic-disease formulations; relevant comparable for specialty branded strategy though larger and more diversified than Medsol.

Broad incumbents

  • Cipla: One of India's largest pharmaceutical incumbents with broad branded-formulations portfolio covering respiratory, cardiology, and chronic-disease categories that include osteoporosis therapeutics.
  • Mankind Pharma: One of India's largest domestic pharma companies with extensive branded generics portfolio across chronic and acute segments; broader scale and reach than Medsol but overlapping chronic-disease franchises.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Medsol social profiles

Digital presence

Medsol financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medsol leadership team

Management profile

Number of profiles

Medsol funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medsol M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medsol

What does Medsol do?

Medsol develops, manufactures, and markets branded pharmaceutical formulations with a primary focus on the osteoporosis therapeutic segment, including bisphosphonate products (Alensol/Alendronate, Osteoplus/Risedronate, Ibanplus/Ibandronic acid) and combination products such as Alensol-D (Alendronate + Vitamin D). Alongside prescription drugs, the company sells pain management (Tremsol), gastrointestinal (Paro-D), and dietary supplement products (Fresh-AD, Calcite). Medsol also delivers patient education and support services in hospital and home settings, and provides pharmaceutical sales force capability training (product training, sales training, territory management).

Is Medsol a public or private company?

Medsol is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Medsol founded?

Medsol was founded in 2010. It employs 51 to 100 people.

Where is Medsol based?

Medsol is headquartered in Noida, India, in the Asia region.

How does Medsol make money?

Three revenue lines are on record. Pharmaceutical Products are the primary driver. The others are training Services and patient Education Services.

Who are Medsol's main competitors?

Direct peers on record are Ipca Laboratories, Emcure Pharmaceuticals, Alkem Laboratories, USV Private Limited, Eris Lifesciences and Macleods Pharmaceuticals. Regional players are Alembic Pharmaceuticals and Natco Pharma. Broad incumbents are Cipla and Mankind Pharma.

Does Medsol have an API?

No public API is recorded for Medsol.

What industry is Medsol in?

Medsol's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales